tbuckley/cabot-search huggingface dataset:
Flexible Pressure, Humidity, and Temperature Sensors for Human Health Monitoring
Authors: Jiaqi Li, Zhengping Fang, Dongsong Wei, Yan Liu
Journal: Advanced Healthcare Materials (2024)

Abstract The rapid advancements in artificial intelligence, micro‐nano manufacturing, and flexible electronics technology have unleashed unprecedented innovation and opportunities for applying flexible sensors in healthcare, wearable devices, and human–computer interaction. The human body's tactile perception involves physical parameters such as pressure, temperature, and humidity, all of which play an essential role in maintaining human health. Inspired by the sensory function of human skin, many bionic sensors have been developed to simulate human skin's perception to various stimuli and are widely applied in health monitoring. Given the urgent requirements for sensing performance and integration of flexible sensors in the field of wearable devices and health monitoring, here is a timely overview of recent advances in pressure, humidity, temperature, and multi‐functional sensors for human health monitoring. It covers the fundamental components of flexible sensors and categorizes them based on different response mechanisms, including resistive, capacitive, voltage, and other types. Specifically, the application of these flexible tactile sensors in the area of human health monitoring is highlighted. Based on this, an extended overview of recent advances in dual/triple‐mode flexible sensors integrating pressure, humidity, and temperature tactile sensing is presented. Finally, the challenges and opportunities of flexible sensors are discussed.
CN51 A scoping review of interventions to enhance cancer nurses' psychological well-being, occupational health and resilience
Authors: N. Dodlek, R. Semerci, A. Charalambous, G. Kotronoulas, C. Díez de los Ríos de la Serna, D. Protogiros, S. Islamcevic, V. Sulosaari
Journal: Annals of Oncology (2024)
CN48 Pilot evaluation of RCC4Nurses to enhance nursing education and practice in survivorship care of people with advanced renal cell carcinoma in Europe
Authors: G. Kotronoulas, C. Díez de los Ríos de la Serna, D. Kelly, A. Drury, W.H. Oldenmenger, C. Papadopoulou, T. Wiseman
Journal: Annals of Oncology (2024)
CN47 Consensus research priorities for cancer nursing in Europe: A Delphi study
Authors: A. Drury, M. Dowling, S. Colomer-Lahiguera, N. Efstathiou, C.J. Semple, P. Fernández Ortega, K.B. Dieperink, E. Pape, G. Kotronoulas, S.S.A. Miguel, G. Bagcivan
Journal: Annals of Oncology (2024)
CN59 Activity and outcomes of a Translational Research Unit coordinated by nursing
Authors: M.P. Andueza, E. Navarcorena Zabalza, Y. Iragorri Barberena, M. Ayensa Burgui, I. Gracia Ilundain, I. Navamuel Andueza, A. Ojer Perea, M. Navamuel Andueza, M.F. Sanmamed, M.E. RodrÍguez-Ruiz, R. Pio, A. Gonzalez Hernandez, M.A. Fortuño, J.P. de Torres, L.M. Seijo Maceiras, M.D. Lozano, I. Melero, L. Montuenga, J.L. Perez Gracia, M. Ocon
Journal: Annals of Oncology (2024)
CN46 Evaluation of efficacy of controlled cooling of the extremities for prevention of chemotherapy-induced peripheral neuropathy and conservation of dose intensity: A Dutch, nurse led observational pilot study
Authors: C. Roth, L. Kamer, A.E.C.A.B. Willemsen, W.M. Tonis, M.A. Klinkhamer
Journal: Annals of Oncology (2024)
CN39 Exploring the pleasure of eating within children undergoing chemotherapy
Authors: M. Khlif, H. Ben Mansour, H. Mrad, Y. Zenzri, J. Majdoub, F. Letaief-Ksontini, A. Mokrani, M. Ayadi, N. Chraiet, H. Rais, K. Meddeb, A. Mezlini
Journal: Annals of Oncology (2024)
CN37 Use of pictograms (picto) for outpatients treated for cancer and monitored by telehealth: A feasibility and proof of concept study
Authors: C. Boiteau, D. Vernerey, S. Paget-Bailly, J. Henriques, J. Fritzsch, N. Alarcon, C. Ganter, E. Kempf, C. Tournigand
Journal: Annals of Oncology (2024)
CN29 Short term effects of self-care behaviours on quality of life for patients on oral anticancer agents
Authors: M. Di Nitto, F. Lacarbonara, S. Ucciero, T. Bolgeo, V. Damico, G. Ghizzardi, S.R. Zerulo, R. Alvaro, F. Torino, E. Vellone
Journal: Annals of Oncology (2024)
CN24 Experience with the routine use of ePROMs in nurse and pharmacist-led telephone clinics for patients with prostate cancer
Authors: K. O'Connor, T. Nuamek, I. Fornacon-Wood, A. Robinson, J. Lyons, H. Coleman, A. Khan, K. Patel, A. Choudhury, R. Conroy, W. Croxford, A. Hudson, J. Logue, Y.P. Song, A. Tran, J. Wylie, J. Yorke, C. Faivre-Finn, M.J. Serra, J. Price
Journal: Annals of Oncology (2024)
1349P A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
Authors: F. Facchinetti, A. Camerini, C. Bennati, P. Bordi, E. De Carlo, F. Mazzoni, G. Metro, F. Bertolini, L. Longo, S. Ricciardi, S. Pilotto, E. Bria, D. Giardina, F. Passiglia, D.L. Cortinovis, V. Scotti, S. Novello, M. Tognetto, M. Di Maio, M. Tiseo
Journal: Annals of Oncology (2024)
1313P Patient-reported outcomes (PROs) in the LUMINOSITY trial: Evaluating telisotuzumab vedotin (Teliso-V) in patients (Pts) with c-Met protein overexpressing (OE), EGFR wildtype, non-squamous non-small cell lung cancer (NSQ NSCLC)
Authors: N. Girard, S. Lu, J. Bar, Q. Xu, S. Ng, R. Sen, Z. Majd, I. Nsiah, C. Ratajczak, M.S. Xia, S. Karve, D.R. Camidge
Journal: Annals of Oncology (2024)
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC
Authors: U. Joshi, S. Gaire, S.K. Yadav, P. Budhathoki, C. Niu, S.K. Low, V. Agrawal, M. Shafique
Journal: Annals of Oncology (2024)
1348P First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
Authors: J.B. Kuon, E. Von der Heyde, P. Sadjadian, M. Bischoff, A. Hassler, A. Althoff, S. Wilop, D.M. Behringer, W. Blau, G. Hübner, D. Flieger, C. Ziske, M. Groschek, H-E. Laack, H. Mueller-Huesmann, C. Schumann, D. Waldenberger, S. Gütz
Journal: Annals of Oncology (2024)
1311P Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial
Authors: D. Rodriguez Abreu, R. Veillon, M. Ravoire, J.L. Gonzalez-Larriba, F.J. Orlandi, T. Nagy, L.G. Paz-Ares, C.H. Huang, J. Roubec, N. Isambert, M.R. García Campelo, D.D.A. Matias, F. Ray, P. Celedon, A. Onn, S. Shamai, E. Carcereny, L. Charbonnier, C. Soufflet, E. Esteban González
Journal: Annals of Oncology (2024)
1335P The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)
Authors: M. Hofman, B.C. Agema, J. Degens, D.P. Hurkmans, D.W. Dumoulin, A. Schols, S.L. Koolen, C. Groeneveldt, W.V.D. Worp, L.E. Hendriks, C.H. Van Der Leest, J.G. Aerts, R.H. Mathijssen, A-M.C. Dingemans, R. Langen, S. Bins
Journal: Annals of Oncology (2024)
1351P Heme-oxygenase-1 (HO-1) as a potential biomarker for ICIs in patients with advanced lung cancer
Authors: F. Biello, V. Martini, G. Borra, S. Genestroni, C. Branni, J. Gennari, R. Ben Ayed, S. Gobbato, L. Negrini, R. Alsati, G. Siffredi, F. Invernizzi, A. Sica, A. Gennari
Journal: Annals of Oncology (2024)
1342P The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status
Authors: W. Shalata, N. Maimon, A. Agbarya, A. Yaakobson, Y. Dudnik, A.Y. Cohen, A. Meirovitz
Journal: Annals of Oncology (2024)
1366P Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort
Authors: J. Mazieres, L. Houvet, S. Mallah, A. Rabeau, L. Bigay-Game, R. Schwob, J-M. Alliot, V. Susplugas, V. Domange
Journal: Annals of Oncology (2024)
1368P Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
Authors: F. Moinard-Butot, J-B. Barbe-Richaud, J. Lasvergnas, J. Ancel, G. Justeau, L. Bender, H. Le Floch, C. Chouaid, O. Bylicki, R. Schott
Journal: Annals of Oncology (2024)
1302P MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
Authors: B.C. Cho, M-J. Ahn, T.M. Kim, S-W. Kim, J-Y. Han, C. Kim, B. Shim, C. Ricordel, A.E. Drilon, J-L. Pujol, J.E. Gray, L. Villaruz, G. Blumenschein, J. Perez, D.A. Modi, M. Kaul, S. Patel, Y. Hao, E. Kim, H. Magnan
Journal: Annals of Oncology (2024)
1317P Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results
Authors: B. Godbert, E. Gobbini, M. Zysman, C. Decroisette, H. Lena, D. Moro-Sibilot, F. Guisier, T. Egenod, S. Couraud, F. Brellier, A. Fleuriet, Y. Khalife, N. Girard
Journal: Annals of Oncology (2024)
1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Authors: V. Gounant, L. Greillier, C. Mascaux, F. Pinquie, D. Carmier, L. Moreau, B. Roch, D. Debieuvre, X. Dhalluin, E. Giroux-Leprieur, E. Berton, A. Rabeau, J. Raimbourg, A. Dixmier, C. Naltet, A. Khalil, L. Ezzeddine, A. Langlais, F. Morin, M. Duruisseaux
Journal: Annals of Oncology (2024)
1362P Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)
Authors: O.F. Khan, M. Salluzzi, R. Bridges, S. Kelly, J. Riskas, S.A. Haider, O. Samorodova, J. Hennessy, V. Sivan, D. Shah, A. Mitchell, F. Baldauf-Lenschen, F.S. Torres, S. Raman, N.B. Leighl
Journal: Annals of Oncology (2024)
1343P Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
Authors: A. De Giglio, L. Zullo, A. Di Federico, M. Cani, M. Aldea, V. Favorito, A. Sadowska, L.E. Hendriks, T. Gorría Puga, L. Mezquita, F. Tabbò, S. Novello, A. Ardizzoni, B. Besse, F. Gelsomino
Journal: Annals of Oncology (2024)
1293P Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
Authors: B.J. Solomon, A.E. Drilon, L.J. Wirth, A. Szpurka, X. Rao, A.C. Massey, S. Barker, J. Wright, H. Won, M.E. Cabanillas
Journal: Annals of Oncology (2024)
1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience
Authors: A.J. Alghabban, A.G. Sacher, F.A. Shepherd, P.A. Bradbury, L. Eng, G. Liu, D. Xie, I. Wozniczka, M. Saf, L. Le, M. Rabey, T. Zhang, P. Sabantini, N.B. Leighl
Journal: Annals of Oncology (2024)
1298P Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD)
Authors: X. Le, C.S. Baik, M. Nagasaka, T. Patil, S.S. Maruti, S. Stanhope, N.A. Kaya, S. Herbertz, C.M. Lovly
Journal: Annals of Oncology (2024)
1340P A phase II study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for pts with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade
Authors: B. El Osta, J. Carlisle, C. Steuer, F.A. Larijani, M. Dhodapkar, M. Rupji, Z. Chen, Y. Liu, T.K. Owonikoko, S.S. Ramalingam, T.A. Leal
Journal: Annals of Oncology (2024)
1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)
Authors: N. Reinmuth, L.G. Paz-Ares, M.C. Garassino, S. Baijal, J. Bennouna, D.B. Daniel, P. Garrido Lopez, T. Kato, I. Percent, A. Rittmeyer, H.J. Soto Parra, S. Mekan, M. Patel, M.A. Radford, P. Zhang, C.G. Pelligra, E. Felip
Journal: Annals of Oncology (2024)
1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Authors: J.W. Riess, J. Miao, P. Wheatley-Price, K.L. Reckamp, D. Kozono, M.W. Redman, M.J. Edelman, B. Faller, L. Villaruz, L. Corum, A. Gowda, G. Srkalovic, R. Osarogiagbon, M. Baumgart, D.R. Gandara, E.S. Sokol, H. Borghaei, J.E. Gray, R.S. Herbst, K. Kelly
Journal: Annals of Oncology (2024)
1310P SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC
Authors: J. Wang, L. Wu, Z. Song, X. Li, T. Liu, C. Liu, N. Xing, J. Xiao, J. Zhong, Y. Wu, Z. Lin, Z. Zhang, S. Wang
Journal: Annals of Oncology (2024)
1323P RATIONALE-307 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC
Authors: Z. Wang, X. Yu, J. Zhao, Y. Yu, J. Wu, R. Ma, Z. Ma, J. Cui, N. Zhao, L. Liang, J. Fan, J. Wang
Journal: Annals of Oncology (2024)
1341P Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study
Authors: Y. Katayama, T. Yamada, R. Sawada, T. Harada, Y. Chihara, A. Yoshimura, S. Shiotsu, A. Okada, T. Yamada, Y. Takemura, T. Kohichi
Journal: Annals of Oncology (2024)
1332P Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases
Authors: T. Iuchi, M. Shingyoji, H. Ashinuma, S. Mizuno, Y. Hasegawa, T. Setoguchi, J. Hosono, T. Sakaida
Journal: Annals of Oncology (2024)
1333P Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study
Authors: L.F-G. Payen, S. Couraud, A. Carrot, G. Lescuyer, M. Piecyk, S. Calattini, A. Gelot, E. Aubret, J. Dubreuil, M. Raffin, J. Balandier, E. Grolleau, O. Pelton, F. Subtil, M. Duruisseaux, B. You
Journal: Annals of Oncology (2024)
1300P Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
Authors: M. Wiesweg, A. Alaffas, A. Rasokat, F.C. Saalfeld, M. Rost, C. Assmann, F. Herster, M. Hilbrandt, F. Griesinger, C. Kropf-Sanchen, M. Reck, J. Kulhavy, A. Stenzinger, M. Sebastian, M.H.H. Schuler, M. Wermke, N. Frost, H-G. Kopp, P. Christopoulos, M. Scheffler
Journal: Annals of Oncology (2024)
1326P Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Authors: S. Daher, W. Shalata, L. Biras, A. Zer, N. Shirron, T.G. Goshen - Lago, Y. Dudnik, A.Y. Cohen, A. Yaakobson, D. Urban, H. Gantz Sorotsky, S. Shamai, A. lobachov, T. Shentzer Kutiel, M.T. Moskovitz, J. Bar
Journal: Annals of Oncology (2024)
1345P Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial
Authors: W.F. Fang, Y. Yang, Y. Huang, Y. Zhao, Y. Zhang, T. Zhou, G. Chen, S. Zhao, Y. Ma, S. Hong, H. Zhao, L. Zhang
Journal: Annals of Oncology (2024)
1438P First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Authors: Y-K. Kang, M.A. Shah, K. Shitara, J.A. Ajani, F. Lordick, E. Van Cutsem, D.H. Ilson, S.J. Klempner, K. Yamaguchi, T. Nakajima, Y.J. Cao, R. Li, D. Moran, R.R. Pophale, R. Ranganath, R-H. Xu
Journal: Annals of Oncology (2024)
1319P Impact of concomitant co-medications on survival with first-line pembrolizumab in 43,000 French patients with advanced NSCLC
Authors: A. Rousseau, S. Foulon, N. Simon-Tillaux, S. Michiels, A. Lolivier, J. Bonastre, D. Planchard, F. Barlesi, J. Remon Masip, P. Lavaud, M. Aldea, M. Frelaut, C. Parisi, C. Le Pechoux, A. Botticella, A. Levy, A. Gazzah, B. Besse
Journal: Annals of Oncology (2024)
1307P Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)
Authors: J. Cadranel, H. Curcio, Y. Oulkhouir, S. Couraud, R. Gille, J. Mazieres, A-C. Métivier, N. Girard, M. Wislez, F. Guisier, H. Almotlak, X. Quantin, C. Bardel, C. Naltet, A-C. Madroszyk Flandin, B. Roch, L. Greillier, C. Clément, L. De Gunten, V. Gounant
Journal: Annals of Oncology (2024)
1290P Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
Authors: M.G. Krebs, S. Lu, Y. Fan, Y. Yu, A.E. Drilon, S. Siena, C. Xue, D. Bradley, X. Hu
Journal: Annals of Oncology (2024)
1325P TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Authors: F. Skoulidis, S. Jabbour, E.B. Garon, P. Iyengar, G. Scagliotti, L. Ferrer, G. Etchepare, O. Gallinato, J. Faure, P. Bernard, T. Colin, P. Menu, Y. Lin, L. Cai, J. Faria, A. Remorino, L. Luciani-Silverman, K.P. Miller, D. Dellamonica, Y. Zhang
Journal: Annals of Oncology (2024)
1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Authors: F. Skoulidis, B.T. Li, M.J. Hochmair, R. Govindan, M. Vincent, A.J. Van Der Wekken, N. Reguart Aransay, K.J. O'Byrne, N. Girard, F. Griesinger, M. Nishio, S. Häfliger, C. Lindsay, N. Reinmuth, A. Paulus, P. Papakotoulas, C. Obiozor, C. Nduka, Y. Wang, A.J. De Langen
Journal: Annals of Oncology (2024)
1330P Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization
Authors: Y. Xu, X. Gao, M. Chen, X. Liu, W. Zhong, J. Zhao, R. Pan, M. Wang
Journal: Annals of Oncology (2024)
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
Authors: G. Mazzaschi, C. Marrocchio, L. Moron Dalla Tor, L. Leo, A. Dodi, P. Tamarozzi, M. Balbi, G. Milanese, G. Monica, S. D'Agnelli, B. Lorusso, M. Pluchino, R. Minari, A. Leonetti, P. Bordi, F. Perrone, S. Buti, F. Quaini, G. Roti, N. Sverzellati, M. Tiseo
Journal: Annals of Oncology (2024)
1301P BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database
Authors: A. Russo, C. Sini, D.L. Cortinovis, L.A. Muscarella, F. Perrone, E. Bria, S. Grisanti, P.L. Piovano, A. Veccia, L. Antonuzzo, F. Citarella, L. Belluomini, M.L. Reale, D. Pignataro, E. Roca, L. Calvetti, F. Passiglia, S. Novello, E. Baldini
Journal: Annals of Oncology (2024)
1318P Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)
Authors: C. Zhou, Z. Wang, M. Sun, L. Cao, Z. Ma, R. Wu, Y. Yu, W. Yao, S. Sun, J. Chen, W. Zhuang, J. Cui, X. Chen, Y. Lu, C. Hu, J. Wang, Q. Wang, B. Wang, H. Dai, J.J. Yang
Journal: Annals of Oncology (2024)
1334P PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis
Authors: N. Frost, M. Wiesweg, A. Rasokat, J. Kulhavy, J. Kollmeier, N. Reinmuth, H. Lüders, J. Roeper, A. Rittmeyer, S. Heinzen, F.C. Saalfeld, C. Wesseler, D. Kauffmann-Guerrero, P. Christopoulos, M. Kemper, M. Collienne, E. Berezucki, T.R. Overbeck, C. Kropf, M. Reck
Journal: Annals of Oncology (2024)
1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)
Authors: M. Pérol, W. Li, N.A. Pennell, G. Liu, Y. Ohe, F.G.M. De Braud, M. Nagasaka, E. Felip, A. Xiong, Y. Zhang, H. Fan, X. Wang, B. Yan, S. Li, M. Chen, L. Bazhenova, C. Zhou
Journal: Annals of Oncology (2024)
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Authors: A. Di Federico, M.F. Chen, A. Pagliaro, F.R. Ogliari, P. Stockhammer, M. Aldea, M. Grant, A. De Giglio, J.V. Alessi, F. Pecci, F. Gelsomino, M.V. Negrao, R. Ferrara, M. Awad, G.J. Riely, A. Ardizzoni, D. Planchard, M.D. Offin, B.E. Johnson, B. Ricciuti
Journal: Annals of Oncology (2024)
1308P Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
Authors: L.V. Ruge, F. John, H. Scharpenseel, J. Siemanowski-Hrach, J. Fassunke, R. Riedel, R.N. Fischer, S. Michels, A. Eisert, A. Rasokat, A. Kron, M. Serke, J. Kappes, K. Kambartel, U. Siebolts, S. Merkelbach-Bruse, R. Büttner, L. Nogova, J. Wolf, M. Scheffler
Journal: Annals of Oncology (2024)
1320P Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
Authors: A. Prelaj, M. Sacco, V. Miskovic, D. Lorenzini, F. Trovò, A. Zec, L.C. Roisman, L. Provenzano, C. Proto, A. Spagnoletti, C. Silvestri, A. Meya, A. Pedrocchi, E. Sarris, E. Felip, M. Reck, F.G.M. De Braud, G. Lo Russo, A.T. Pearson, M.C. Garassino
Journal: Annals of Oncology (2024)
1296P A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Authors: C. Zhou, X. Li, Q. Yu, R. Ning, M. Sun, Q. Wang, A. Liu, H. Tang, X. Tian, Y. Zhou, Z. Wei
Journal: Annals of Oncology (2024)
1329P Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naïve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results
Authors: P. Ma, W. Gao, H. Shen, L. Xu, R. Wang, X. Chen, J. He, Y. Liu, J. Sun, Y. Shu
Journal: Annals of Oncology (2024)
1303P METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence
Authors: X. Le, C. Aggarwal, A. Simmons, S.A. Crawford, S. Ng, C. Chen, S. Karve, S. Stein, K. Woll, P.J. Ansell, A. Mistry, D. Bryant, I.I. Wistuba
Journal: Annals of Oncology (2024)
1291P Real-world treatment and overall survival (OS) in patients (pts) with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in England between 2014 and 2023
Authors: A. Greystoke, G. Emanuel, C. Rault, J. Penrod, C. Calvet, Y. Yuan, S. Lay-Flurrie, E. Markov, E. Asenova, V. Saglimbene, A. Lee
Journal: Annals of Oncology (2024)
1306P Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study
Authors: B. Han, J. Lu, H. Zhong, T. Chu, W. Zhang, M. Hu, C. Shi, L. Xiong, A. Gu, H. Wang, Y. Lou, Y. Zhang, R. Zhong, Z. Gao
Journal: Annals of Oncology (2024)
1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
Authors: E. Pons-Tostivint, I. Okamoto, J. Sands, N. Girard, R. Cornelissen, M.H. Hong, L.G. Paz-Ares, D. Vicente Baz, S. Sugawara, M. Cobo Dols, M. Pérol, C. Mascaux, S. Kitazono, H. Hayashi, A.E. Lisberg, O.J. Juan Vidal, Y. Zhang, M. Chargualaf, D. Uema, M-J. Ahn
Journal: Annals of Oncology (2024)